Japanese generics giant Sawai appears to be turning a corner, but the impact of National Health Insurance pricing revisions continues to hold the firm – and the rest of the country’s generics industry – back.

Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.

In 2024, Viatris will initiate the second phase of its long-term business plan, which will see it step away from the perceived volatility of the generics space and begin to move toward innovative and high-growth products. The past year has seen it lay the groundwork for this pivot, shedding surplus business units and making significant hires from the branded space.

Hearing loss lacks pharmacological treatment options, with patients instead relying on medical devices or going untreated. In Vivo spoke to French biotech Sensorion, which is targeting a number of hearing loss indications with small-molecule drugs and gene therapies.

As the nationwide shortage of Adderall continues in the US, Elite Pharmaceuticals has announced the first shipment of its generic version to partner Prasco.

Scottish biotech Mironid is in the preclinical stages of developing a treatment for autosomal dominant polycystic kidney disease, a genetic condition which for around half of patients can led to kidney failure by the time they reach 60 years of age. In Vivo spoke to chief medical officer Cass Kelleher about the company’s development strategy.